Ondine Biomedical, Inc. (VF5) Stock Statistics & Valuation Metrics

Ondine Biomedical, Inc. has a market cap or net worth of €88.77M. The enterprise value is €109.78M.

Ondine Biomedical, Inc. has 518,366,940 shares outstanding. The number of shares has decreased by -2.65% in one year.

Ondine Biomedical, Inc.’s return on equity (ROE) is -8.48 and return on invested capital (ROIC) is -769.72%.

The current PE Ratio of Ondine Biomedical, Inc. is ―. Ondine Biomedical, Inc.’s PEG ratio is 0.28.

In the last 12 months, Ondine Biomedical, Inc. had revenue of 2.65M and earned -29.59M in profits. Earnings per share was -0.06.

In the last 12 months, operating cash flow was -23.89M and capital expenditures -116.79K, giving a free cash flow of -24.01M billion.

Ondine Biomedical, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―

Ondine Biomedical, Inc. upcoming earnings date is Sep 30, 2026, Before Open (Confirmed).

Ondine Biomedical, Inc. as a current ratio of 1.23, with Debt / Equity ratio of 11.85%

In the past 12 months, Ondine Biomedical, Inc. has paid 0.00 in taxes.

Ondine Biomedical, Inc. EV to EBITDA ratio is -2.21, with an EV/FCF ratio of -2.70.

Ondine Biomedical, Inc. has €10.58M in cash and marketable securities with €413.50K in debt, giving a net cash position of €10.17M billion.

Gross margin is 41.14%, with operating margin of -1132.54%, and net profit margin of -1115.53%.

The average price target for Ondine Biomedical, Inc. is ―, which is 11.43% higher than the current price. The consensus rating is ―